Our latest research, company updates and industry insight
The ClearSky China team exhibited at the 2018 Shanghai Ruijin International Forum of Translational Research in Neurodegenerative Disease in March. It was also the second annual meeting of neurodegenerative diseases of The Chinese Neuroscience Society. Around 300...
Evolutionary algorithms are inspired by the biological model of evolution and natural selection proposed by Darwin. We have used evolutionary algorithms to recognise movement characteristics of Parkinson’s.
Complex figure tests are widely used neuropsychological tests where participants are asked to reproduce a complicated line drawing, first by copying it freehand and then drawing it from memory.
Ruijin Hospital in Shanghai together with ClearSky Medical Diagnostics has launched the world’s largest single centre clinical validation study for diagnosing Parkinson’s.
Dr Stephen Smith will be a speaker at the sell-out Parkinson’s UK 2017 Research Support Network Conference in Birmingham in October. The conference provides people affected by Parkinson's the ideal opportunity to learn more about the work supported by Parkinson’s UK –...
ClearSky Medical Diagnostics is looking forward to attending and exhibiting at MEDICA 2017, the international medical trade fair. MEDICA is the world’s largest event for the medical sector – more than 128,000 international trade visitors from 70 countries attended the...
Dr Keith Morris has been appointed the Quality Assurance and Regulatory Affairs Counsel for ClearSky Medical Diagnostics.
Diagnosis of Parkinson’s can be difficult to confirm by conventional assessments – relying on the judgement of a clinician observing and rating a patient’s movements, or costly brain scans.
ClearSky Medical Diagnostics headed to Vancouver at the start of June for the 21st International Congress of Parkinson’s Disease and Movement Disorders.
The ClearSky Medical Diagnostics (CSMD) team recently enjoyed a successful trip to China, introducing technologies that make the diagnosis and monitoring of neurodegenerative conditions both easier and more reliable.
ClearSky’s LID-Monitor, a device for tracking movements of people with Parkinson’s over a 24-hour period, has received the CE Mark of approval – meeting EU safety, health or environmental requirements.
ClearSky has enjoyed success in a prestigious investment competition aimed at helping innovative businesses develop their ideas and receive valuable mentor support.